Oncopeptides' Pepaxti achieves 48% response rate in Italian real-world myeloma study

• Oncopeptides will present two real-world Pepaxti studies at the American Society of Hematology meeting in New Orleans, December 12-15, 2026.
• The retrospective studies covered 82 heavily pretreated multiple myeloma patients in Spain and Italy, showing activity with Pepaxti combined with dexamethasone.
• Spanish findings showed activity in patients previously treated with immunotherapies; Italian results supported subsequent treatment, including newer immunotherapies.
• Side effects were predominantly blood-related and manageable, with few patients permanently discontinuing treatment because of adverse events.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncopeptides AB published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.